FinTechFunding

PharmAust: Continues testing COVID-19 treatment

  • PharmAust (PAA) has revealed preliminary results show its drugs are effective in inhibiting COVID-19 in human lung cells
  • Researchers in Melbourne have been testing the effect monepantel (MPL) and monepantel sulfone (MPLS) has on the deadly virus
  • This recent testing found MPL and MPLS inhibited COVID-19 in human lung cells by up to 95 per cent
  • PharmAust said following these initial results, further testing will now undertaken to better understand the drug’s effect
  • PharmAust’s Chief Scientific Officer, Richard Mollard, also said the was very pleased with these latest results
  • Shares in PAA are trading 4.26 per cent in the green at 24.5 cents each
Previous article
Perpetual Resources: Receives positive wet screening test results
Next article
Metalicity: Confirms further high-grade gold at Liepold
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Business Banking Fintech Slash Reaches Unicorn Status

The fintech startup achieves a valuation of over $1 billion.Highlights: Slash has been valued at over $1 billion.The...
FinTech

Amex Strengthens Digital Services with AI Expense Management Acquisition

American Express to acquire Hyper to enhance its business offerings.Highlights: American Express announces the acquisition of AI startup...
FinTech

UK Banks Strengthen Cybersecurity with Anthropics Mythos Model

New collaboration enhances banks' defense against cyber threats.Highlights: UK banks to access Anthropics Mythos model in the upcoming...
FinTech

UK Banks to Gain Access to Anthropic Cybersecurity Model Next Week

New collaboration enhances cybersecurity for UK banking institutions.Highlights: UK banks set to access Anthropic's cybersecurity model soon.Collaboration aims...